Sabby Management’s Regenxbio RGNX Stock Holding History

Sabby Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-81	Closed	-$269K	–	177
2017 Q4	$269K	Buy	81 +3	+4%	+$90	0.02%	117
2017 Q3	$257K	Buy	+78	New	+$1.75K	0.02%	121

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sabby Management's RGNX Position: Q1 2017 in Review

Sabby Management sold out of Regenxbio (RGNX) in Q1 2017, closing a stake of 48,400 shares — an estimated $898K sold.

Sabby Management first reported a position in RGNX in Q4 2015 and held it in 5 quarters. The position peaked at $3.69M in Q3 2016. 85 funds tracked by Wall St. Rank hold RGNX as of Q1 2017.

Sabby Management reported no remaining Regenxbio position as of Q1 2017 after selling out during the quarter.
Sabby Management sold 48,400 Regenxbio shares in Q1 2017, an estimated $898K.
Sabby Management first reported a position in Regenxbio in Q4 2015 and held it in 5 quarters.
Sabby Management's Regenxbio position peaked at $3.69M in Q3 2016.
85 funds tracked by Wall St. Rank held Regenxbio as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.